JOHNSON & JOHNSON 853260 - wohl das am konstantesten wachsende Unternehmen der Welt (Seite 54)

[shaba]

Antwort auf Beitrag Nr.: 35.947.703 von spaceistheplace am 14.11.08 14:55:54

(bebe, fenjal, tampons etc.)

und die windeln werden auch regelmässig "gefüllt"

das mit den aktiensplits ist natürlich um vieles besser, werde mich darauf einstellen!

ebenfalls ein angenehmes wochenende!

gruss,
shaba

[spaceistheplace]

Antwort auf Beitrag Nr.: 35.947.653 von shaba am 14.11.08 14:49:45

giganten der pharmabranche

Pharma macht rd. 1/3 aus, Medtech noch mal so viel und consumer staples (bebe, fenjal, tampons etc.) noch mal ein Drittel, also breit aufgestellt. gerade die Pharmabranche wächst aktuell nicht.


ich gehe davon aus dass du bereits längere zeit bei JNJ investiert bist und dadurch auch am letzten stand.

jou, mit Unterbrechungen seit 1995


wie siehst du das target innerhalb der nächsten 12 monate? ist 70$ realistisch?

habe ich nicht, bin Langfristinvestor und da habe ich keine Kursziele. Langfristig zählen nur die Aktiensplits...

ich werde gerne mitarbeiten und mir alles zugängliche und auch interessante hier einstellen.

jou, nur zu! Dann muss ich es hier nicht alleine machen wie bisher.

Gruss und schönes Wochenende
space

[shaba]

Antwort auf Beitrag Nr.: 35.947.473 von spaceistheplace am 14.11.08 14:30:57

dankeschön spaceistheplace,

ja ich habe auch den eindruck dass ich in zeiten wie diesen hier sehr gut aufgehoben bin.
die website und die fast täglich eingehenden meldungen über diesen giganten der pharmabranche, sind sehr überzeugend-ebenso das täglich gehandelte volumen.

ich gehe davon aus dass du bereits längere zeit bei JNJ investiert bist und dadurch auch am letzten stand. wie siehst du das target innerhalb der nächsten 12 monate? ist 70$ realistisch?

ich werde gerne mitarbeiten und mir alles zugängliche und auch interessante hier einstellen.

gruß,
shaba

[spaceistheplace]

Antwort auf Beitrag Nr.: 35.943.943 von shaba am 14.11.08 06:15:58

Nachdem ich mich bereits vor einiger Zeit entschlossen habe einen Teil meines Börsenkapitals in diese Aktie zu investieren, begrüße ich alle Investierten und stelle auch eine neue Meldung hier ein.

willkommen im JNJ-Club, shaba!
Wirst es nicht bereuen! JNJ ist eines der besten Unternehmen überhaupt. ich kann es nur noch mal wiederholen: seit 47 Jahren steigende Gewinne jährlich, steigende Divis. Zudem kaum Schulden hoher cash flow...
Super Management und die produkte erhaben

Gruss space

[shaba]

Nachdem ich mich bereits vor einiger Zeit entschlossen habe einen Teil meines Börsenkapitals in diese Aktie zu investieren, begrüße ich alle Investierten und stelle auch eine neue Meldung hier ein.

gruss
shaba



New Antibiotic Against Serious Infections - Receives First Approval in Europe
ZEVTERA™ A Broad-spectrum, Anti-MRSA Cephalosporin Antibiotic to Treat Complicated Skin and Soft Tissue Infections Approved in Switzerland

Baar, Switzerland (November 13, 2008) - Swissmedic, the Swiss agency for therapeutic products, has approved ZEVTERA™ (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone.

Ceftobiprole is licensed from and co-developed with Basilea Pharmaceutica Ltd. Janssen-Cilag will market ceftobiprole in Switzerland under the trade name ZEVTERA™. Swiss based Basilea Pharmaceutica Ltd will co-promote the drug in key European markets and North America.

Ceftobiprole is the first, broad-spectrum, anti-MRSA cephalosporin antibiotic with activity against a range of difficult-to-treat Gram-positive and Gram-negative hospital- and community-acquired pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa1. In clinical trials, ceftobiprole has demonstrated high cure rates in patients with complicated skin infections, including those caused by the potentially deadly MRSA.

Data from the European Antimicrobial Resistance Surveillance System (EARSS) show that the prevalence of MRSA - a difficult to treat cause of hospital-and- community acquired infections - while varying considerably among countries, has been rising across Europe for the past six years2.

The use of ceftobiprole in adults for the treatment of complicated soft tissue infections, including diabetic foot infections which have not spread to the bone, is under regulatory review in United States, Australia and in the European Union among other countries. In Canada, ceftobiprole was launched in August 2008 under the trade name ZEFTERA.

About Complicated Skin Infections

Complicated skin and soft tissue infections are among the most common infections in the hospital setting. Staphylococcus aureus is the predominant pathogen in these infections. In recent years, resistant strains, such as MRSA have become increasingly common and have been associated with increased morbidity and mortality. New broad-spectrum antibiotics that cover resistant bacteria such as MRSA, but also clinically important and problematic Gram-negative pathogens, address a high-unmet medical need in the treatment of severe skin and soft tissue infections.

Patients with chronic wounds or those who have recently received antibiotics may also be infected by Gram-negative pathogens. This is frequently the case for diabetic patients with foot infections. Adequate treatment of diabetic foot infections can require hospitalization, surgery and broad-spectrum intravenous antibiotics.

About Ceftobiprole

Ceftobiprole, the first anti-MRSA cephalosporin to be approved, is an intravenous antibiotic that belongs to the class of antibacterial drugs known as cephalosporins, which are used to treat serious infections caused by a broad range of bacteria, characterized as Gram-negative and Gram-positive, based on a classification process that is used to identify the specific type of bacteria.

Phase III clinical trials have demonstrated that ceftobiprole is clinically efficacious against the following pathogens: Enterobacter cloacae, Enterococcus faecalis, Proteus mirabilis, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa.

The Janssen-Cilag company have a long and successful track record in developing and marketing treatments for a wide variety of conditions such as infectious disease, HIV, pain management, fungal infections, multiple myeloma, gastroenterological disorders, epilepsy, Alzheimer's disease, schizophrenia, acute bipolar mania, behavioural psychological symptoms of dementia, disruptive behaviour disorders, and autism. More information can be found at http://www.janssen-cilag.com. The Janssen-Cilag companies are part of the Johnson & Johnson family of companies.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Janssen-Cilag's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Janssen-Cilag does not undertake to update any forward-looking statements as a result of new information or future events or developments.

1 Pseudomonas aeruginosa, a gram-negative pathogen, causes a variety of infectious diseases and is the most significant cause of hospital acquired infections particularly in pre-disposed patients with metabolic, haematologic, and malignant diseases.

2 European Antimicrobial Resistance Surveillance System (EARSS) 2005 Annual Report. Available at: http://www.rivm.nl/en/

[spaceistheplace]

J&J Device Tops Drugs In Treating Heart-Rhythm Issue - Study11-11-08 11:51 AM EST | E-mail Article | Print Article

New study data released Tuesday indicate treatment with a catheter-based system made by a Johnson & Johnson (JNJ) unit can help patients avoid recurrence of a common heart-rhythm disorder called atrial fibrillation better than the use of drugs.
This is the first U.S. Food and Drug Administration-vetted clinical trial to show this result, according to J&J's Biosense Webster, which is trying to leverage the data to win FDA approval to market its system for atrial fibrillation. The rhythm problem has already generated a fast-growing market for catheter-based treatment in the U.S., although no company has FDA approval to actually market such devices for this purpose.

Biosense Webster would like to cross that line and be first in a field where competitors include St. Jude Medical Inc. (STJ), Medtronic Inc. (MDT) and Boston Scientific Corp. (BSX), and where unapproved device usage has drawn some scrutiny. Boston Scientific and another company, AtriCure Inc. (ATRC), have each recently disclosed letters indicating a U.S. Justice Department investigation into use of surgery-based systems to treat atrial fibrillation.

An FDA panel of experts will meet on Nov. 20 to review using Biosense Webster's "NaviStar ThermoCool" catheter to specifically treat the rhythm problem.

"The reason we think it's so important [to get approval] is we think it's critical that we be able to participate in the training" for atrial-fibrillation treatment, said Marcia Yaross, vice president of clinical, regulatory and health policy at Biosense Webster. Treatment procedures are complex and there is a steep learning curve.

Atrial fibrillation is a common type of irregular heart rhythm in the U.S., where it affects more than two million people. The problem, which involves very fast and disorderly beating in the heart's upper chambers, can boost the risk of strokes and other complications.

Patients with atrial fibrillation are most often treated with drugs, which frequently don't help. There is a growing market for back-up treatment with medical devices that carefully destroy, or ablate, heart tissue linked to the problem. There are different systems that ablate tissue with energy that are used during regular surgery, or during less invasive procedures where catheters are threaded to the heart through blood vessels.

Catheter-based techniques have been taking over as a preferred option, backed by improving technology that helps doctors find the problem area, said Mark Estes, who is president of the Heart Rhythm Society. The group represents electrophysiologists such as Estes who treat heart-rhythm issues. He practices at Tufts Medical Center in Boston.

The odds of curing atrial fibrillation with one catheter-based procedure are now about 75% to 80%, Estes said.

Avoiding Recurring Problems

Data from the Biosense Webster-backed study were released Tuesday at the American Heart Association's annual scientific conference. A total of 167 patients who had failed treatment with at least one drug were enrolled and tracked for nine months to see whether treatment with different drugs or ablation was more likely to stop symptomatic atrial fibrillation from recurring.

The reduction in recurrence among patients treated with the Biosense Webster system was significantly higher, at 75%, than the 21% reduction seen among patients treated with drugs. There were also fewer serious adverse events at 90 days - a pre-specified follow-up point in the study - among patients treated with the device.

Device-based atrial-fibrillation treatment already represents an approximate $ 1.5 billion global market and a rapidly expanding U.S. market, according to Stanford Group analyst Jan Wald. The annual sales growth profile tops 20%, he said.

Certain devices are approved for atrial-fibrillation treatment overseas, but not in the U.S. The domestic market has still taken off, however, because devices are already available based on FDA clearance for other issues.

This usage has made atrial-fibrillation treatment tricky to study, because patients who have failed one drug may not want to try another - as a study may require - when they have clear access to device treatment.

In the Biosense Webster study, nearly 5,300 patients were screened to get to 167 participants, partially due to this issue. The study looked for patients who had already tried drug treatment because major heart associations have said catheter-based treatment should be reserved for such cases.

Despite such challenges, there are studies underway across the sector aimed at bolstering evidence for device-based treatment, including a St. Jude-supported study examining catheter ablation and an AtriCure study examining its surgical system.

Boston Scientific and Medtronic have long had ablation devices, but recently moved to buy companies that make systems that freeze tissue to treat rhythm issues and also have studies underway aimed at U.S. approval for atrial fibrillation.

Medtronic should soon close on the purchase of CryoCath Technologies Inc., which, if its study goes well, could win FDA approval in 18 months or so to treat atrial fibrillation with its system. Medtronic is also forming a specific atrial-fibrillation business unit within its big heart-rhythm-disease management business.

The push toward FDA approval comes amid some disclosures regarding the Justice Department scrutiny of surgical ablation. AtriCure shares sank last week after it disclosed a letter from the agency, received Oct. 27, regarding an investigation into the company's marketing practices for its system and atrial fibrillation.

Boston Scientific, meantime, disclosed in a Securities and Exchange Commission filing that it received a Justice Department letter on Oct. 24 "informing us of an investigation relating to surgical cardiac ablation system devices to treat atrial fibrillation."

A Justice Department spokesperson couldn't be reached for comment Tuesday regarding the scope of this investigation.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; [e-mail]

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/al?rnd=6NlmY0aFxCN%2F%2BlgX8%2BRclQ%3D%3D. You can use this link on the day this article is published and the following day.

[spaceistheplace]

Antwort auf Beitrag Nr.: 35.911.010 von AlexU am 11.11.08 14:00:58

Weiß jemand was darüber?

neee, sorry. ich habe keine Mitteilung.

Gruss space

[AlexU]

Hi,

ich habe heute einen Brief von meiner Depotbank gekriegt.
Betreff: Kapitalmaßnahme J&J.

K&N (WKN 907665) bietet für jede Aktie von J&J eine eigene Aktie.

Weiß jemand was darüber?

[spaceistheplace]

Antwort auf Beitrag Nr.: 35.883.884 von AlexU am 08.11.08 15:28:00

Hallo Space,
wo siehst du das Kursziel von J&J?

So was habe ich nicht. Ich halte das teil bis zu meiner Rente, oder ves wird vererbt...
Wird dann genau so hoch im Kurs liegen wie jetzt, nur haben wir dazwischen ein paar Splits gesehen...

Ein Verkauf kommt evtl. dann in Betracht, wenn wir soo eine Bewertungsblase haben wie in 2000, sagen wir ein KGV von 40-50. So hoch war es mal in 1986, 1992, 1999. Da lag ne Überteuerung vor, der Kurs ging dann längers seitwärts, nippelte aber auch nicht ab. Die Divis sind ja auch nett...

Gruss space

[AlexU]

Antwort auf Beitrag Nr.: 35.760.050 von spaceistheplace am 30.10.08 10:19:43

Hallo Space,
wo siehst du das Kursziel von J&J?